Biointron has expanded its CRO antibody production services through its RushMab™ small-scale expression packages, offering delivery timelines as fast as 4 days.
The platform is designed to help pharmaceutical and biotechnology companies accelerate antibody discovery and preclinical development workflows.
Biointron is expanding its contract research organization (CRO) antibody production capabilities through its RushMab™ small-scale antibody expression platform, designed to support rapid biologics development and preclinical research. The service offers multiple production formats with turnaround times ranging from four to ten days, targeting biopharma companies seeking faster antibody generation and screening.
The RushMab™ platform includes several service tiers, ranging from plasmid production to purified antibody delivery. The fastest option, RushMab™-Gene, provides transfection-grade expression plasmids within four days, while higher-tier packages deliver purified antibodies, supernatants, and quality-controlled expression materials within eight to ten days. The platform supports IgG, Fab, VHH, and ScFv antibody formats.
From a CRO perspective, the service is intended to address increasing demand for faster antibody production as biologics pipelines expand and drug developers seek to shorten early-stage research timelines. Rapid turnaround can reduce delays in candidate screening, validation, and optimization, helping sponsors move programs forward more efficiently.
Biointron noted that the platform combines speed with quality-control measures including sequencing verification, endotoxin testing, SDS-PAGE analysis, SEC-HPLC characterization, and titer detection depending on the selected package. The company said the service is designed for both small-scale discovery programs and larger antibody research workflows requiring scalable production capacity.
“As biologic pipelines grow and AI-driven candidate generation accelerates, the wet-lab expression step has become the rate-limiting factor in early research programs.”
Mia Deng of Biointron Biological Inc.
Sign up to the free weekly newsletter for all the latest news, resources and podcasts in contract manufacturing. 
